泰格医药
(300347)
| 流通市值：330.67亿 | | | 总市值：502.84亿 |
| 流通股本：5.66亿 | | | 总股本：8.61亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,707,560,174.2 | 1,801,473,935.03 | 6,832,800,615.35 | 5,025,868,260.75 |
| 营业收入 | 3,707,560,174.2 | 1,801,473,935.03 | 6,832,800,615.35 | 5,025,868,260.75 |
| 二、营业总成本 | 3,348,891,613.17 | 1,644,573,250.45 | 6,312,645,254.48 | 4,559,527,495.2 |
| 营业成本 | 2,687,044,293.79 | 1,321,581,301.06 | 4,959,606,315.77 | 3,560,252,024.84 |
| 税金及附加 | 17,215,270.85 | 8,559,140.98 | 34,929,024.09 | 25,585,746.05 |
| 销售费用 | 109,736,247.02 | 56,191,158.6 | 234,658,095.13 | 175,449,787.82 |
| 管理费用 | 353,246,010.52 | 173,425,810.23 | 725,906,444.89 | 530,840,458.53 |
| 研发费用 | 139,365,219.43 | 62,655,948.12 | 257,643,569.77 | 191,239,953.92 |
| 财务费用 | 42,284,571.56 | 22,159,891.46 | 99,901,804.83 | 76,159,524.04 |
| 其中:利息费用 | 32,816,589.51 | - | 90,559,390.82 | - |
| 其中:利息收入 | 7,477,747.22 | - | 15,126,062.26 | - |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -443,323,794.17 | 195,035,877.15 | 42,256,274.39 | 323,191,353.26 |
| 加:投资收益 | -2,431,886.75 | 36,660,390.11 | 433,815,899.7 | 440,220,795.12 |
| 资产处置收益 | -18,083,068.74 | -463,466.46 | 3,650,548.27 | 5,223,121.86 |
| 资产减值损失(新) | -3,598,601.99 | -572,928.54 | -38,961,326.65 | -5,401,777.73 |
| 信用减值损失(新) | 2,721,374.18 | -2,488,564.14 | 1,917,920.09 | -26,908,313.51 |
| 其他收益 | 27,398,667.55 | 20,766,535.53 | 46,585,292.33 | 26,343,546.96 |
| 四、营业利润 | -78,648,748.89 | 405,838,528.23 | 1,009,419,969 | 1,229,009,491.51 |
| 加:营业外收入 | 595,900.99 | 133,522.92 | 2,238,748.93 | 809,111.08 |
| 减:营业外支出 | 2,162,460.04 | 27,742.7 | 8,443,597.94 | 7,037,847.33 |
| 五、利润总额 | -80,215,307.94 | 405,944,308.45 | 1,003,215,119.99 | 1,222,780,755.26 |
| 减:所得税费用 | 105,256,011.83 | 75,860,662.83 | 198,158,945.47 | 131,099,588.8 |
| 六、净利润 | -185,471,319.77 | 330,083,645.62 | 805,056,174.52 | 1,091,681,166.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -185,471,319.77 | 330,083,645.62 | 805,056,174.52 | 1,091,681,166.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -413,159,500.41 | 49,043,121.13 | 887,890,076.31 | 1,020,434,157.81 |
| 少数股东损益 | 227,688,180.64 | 281,040,524.49 | -82,833,901.79 | 71,247,008.65 |
| 扣除非经常损益后的净利润 | 277,720,545.46 | 120,394,081.64 | 355,078,814.5 | 325,942,579.27 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.48 | 0.06 | 1.04 | 1.19 |
| (二)稀释每股收益 | -0.48 | 0.06 | 1.04 | 1.19 |
| 八、其他综合收益 | -176,529,004.82 | -87,366,018.26 | -53,653,137.05 | 9,646,423.79 |
| 归属于母公司股东的其他综合收益 | -134,769,091.18 | -63,703,960.36 | -42,027,176.87 | 8,770,477.73 |
| 九、综合收益总额 | -362,000,324.59 | 242,717,627.36 | 751,403,037.47 | 1,101,327,590.25 |
| 归属于母公司股东的综合收益总额 | -547,928,591.59 | -14,660,839.23 | 845,862,899.44 | 1,029,204,635.54 |
| 归属于少数股东的综合收益总额 | 185,928,267 | 257,378,466.59 | -94,459,861.97 | 72,122,954.71 |
| 公告日期 | 2026-08-29 | 2026-04-29 | 2026-03-31 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |